Journal of Oncology Research and Treatment
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • Adv Oncol Res Treat 2016. 1:2,

Haemolytic Uraemic Syndrome and Its Relation to Metastatic Prostate Adenocarcinoma: A Case Report

Munoz-Unceta N*, Espinosa P, Manneh R, Castellano D and Paz-Ares L
Medical Oncology Department of Hospital Universitario 12 de Octubre, , Madrid, Spain
*Corresponding Author : Munoz-Unceta N, Medical Oncology Department of Hospital Universitario 12 de Octubre, Madrid, Spain, Tel: +60 3-8921 5555, Email: nere.mun@gmail.com

Received Date: Jul 15, 2016 / Accepted Date: Aug 18, 2016 / Published Date: Aug 22, 2016

Abstract

Haemolytic Uraemic Syndrome (HUS) has been rarely related to prostate cancer. The few cases reported in the literature show a better prognosis with the implementation of oncologic treatment. Its pathogenesis is unknown and has never been described as a consequence of treatment with bicalutamide. At the presented case this association couldn’t be dismissed due to its temporal relationship, so surgical castration was carried out. it is important to recognize signs and symptoms of HUS on time because an early intervention is related to a better outcome.

Keywords: Prostate cancer; Acute renal failure

Citation: Munoz-Unceta N, Espinosa P, Manneh R, Castellano D, Paz-Ares L (2016) Haemolytic Uraemic Syndrome and Its Relation to Metastatic Prostate Adenocarcinoma: A Case Report. Adv Oncol Res Treat 2: 109.

Copyright: ©2016 Muñoz-Unceta N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top